Sanofi files patent infringement lawsuit against Merck

Amy Schofield 10 August 2017

Sanofi has launched a new patent infringement suit against US pharma company Merck & Co in the USA.

The suit alleges infringement of two patents relating to Lantus (insulin glargine), Sanofi’s flagship diabetes drug.

Sanofi’s legal action was triggered by a notification received in late June this year, in which Merck stated that it had filed a New Drug Application (NDA) with the US Food and Drug Administration for an insulin glargine vial drug product.

Merck stated that its NDA included a paragraph IV certification challenging all of the Sanofi patents then listed in the FDA Orange Book for the Lantus and Lantus SoloStar products.

Sanofi also filed a suit against Merck in Delaware less than a year ago, which alleged the infringement of 10 patents relating to Lantus.

Sales of Lantus fell 19% to 1.2 billion euros ($1.4 billion) in the latest quarter compared to a year ago due to competition from biosimilars and other biologics. Despite this, Lantus was the French drugmaker's biggest selling product, generating sales of around $6.6 billion in 2016.

Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.